General Information
Drug ID
DR00423
Drug Name
Gefitinib
Synonyms
4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; 6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine; CU-00000000396-1; Gefitini; Gefitinib (JAN/USAN/INN); Gefitinib [USAN]; Gefitinib,Iressa, ZD1839; IRE; Iressa; Iressa (TN); Iressa(TM); Irressat; N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine; ZD 1839; ZD-1839; ZD-1839, Iressa, Gefitinib; ZD1839
Drug Type
Small molecular drug
Indication Breast cancer [ICD11: 2C60-2C6Z] Approved [1]
Urethral cancer [ICD11: 2F78] Approved [1]
Non-small cell lung cancer [ICD11: 2C25] Approved [1]
Ovarian cancer [ICD11: 2C73] Preclinical [1]
Prostate cancer [ICD11: 2C82] Preclinical [1]
Therapeutic Class
Anticancer Agents
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=123631"></iframe>
3D MOL 2D MOL
Formula
C22H24ClFN4O3
Canonical SMILES
COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4
InChI
InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)
InChIKey
XGALLCVXEZPNRQ-UHFFFAOYSA-N
CAS Number
CAS 184475-35-2
Pharmaceutical Properties Molecular Weight 446.907 Topological Polar Surface Area 68.7
Heavy Atom Count 31 Rotatable Bond Count 8
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 8
PubChem CID
123631
PubChem SID
10240807 , 103024897 , 10318995 , 103244983 , 103905343 , 103905344 , 104418951 , 104829175 , 11377941 , 117865087 , 118047033 , 12015033 , 123105108 , 124756943 , 124892204 , 124892205 , 124892206 , 125001914 , 14833109 , 21317853 , 24424016 , 24424024 , 24424026 , 29215403 , 29215404 , 29303859 , 46508649 , 47646567 , 49635529 , 49742641 , 50040863 , 50100103 , 532631 , 53319998 , 53788589 , 53799235 , 56312091 , 56313236 , 56313469 , 57340492 , 61127928 , 7849039 , 8035066 , 81092810 , 85171051 , 92308715 , 92717784 , 93581024 , 99436946 , 99444469
ChEBI ID
ChEBI:49668
TTD Drug ID
D09XZB
DT(s) Transporting This Drug BCRP Transporter Info Breast cancer resistance protein Substrate [2]
OATP1B1 Transporter Info Organic anion transporting polypeptide 1B1 Substrate [3]
OATP1B3 Transporter Info Organic anion transporting polypeptide 1B3 Substrate [3]
P-GP Transporter Info P-glycoprotein 1 Substrate [4]
References
1 Gefitinib was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
3 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
4 Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteers. Br J Clin Pharmacol. 2009 Aug;68(2):226-37.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.